当前位置: 首页 >> 检索结果
823. INTERLACE: not a new standard for cervical cancer chemoradiation.
作者: Primoz Petric.;Jacob Christian Lindegaard.;Maximillian Paul Schmid.;Ina Jürgenliemk-Schulz.;Umesh Mahantshetty.;Christian Kirisits.;Richard Pötter.
来源: Lancet. 2025年406卷10505期806-807页 830. Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.
作者: Lonnie Pyne.;Patrick Rossignol.;Cameron Giles.;Mats Junek.;Patrick B Mark.;Martin Gallagher.;Janak R de Zoysa.;P J Devereaux.;Michael Walsh.
来源: Lancet. 2025年406卷10505期811-820页
Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but their effects in patients with kidney failure requiring dialysis are uncertain. We aimed to assess the efficacy and safety of mineralocorticoid receptor antagonists in this patient population.
834. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
作者: Mazen Noureddin.;Juan P Frias.;Guy W Neff.;K Jean Lucas.;Cynthia Behling.;Pierre Bedossa.;Julie Dubourg.;Doreen Chan.;Mark Burch.;Erica Fong.;Brittany de Temple.;Matt Minerva.;Kim Barrett.;Reshma Shringarpure.;Erik J Tillman.;Timothy Rolph.;Andrew Cheng.;Kitty Yale.
来源: Lancet. 2025年406卷10504期719-730页
Efruxifermin is a bivalent fibroblast growth factor 21 analogue in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to prospectively assess the safety and efficacy of efruxifermin administration for 96 weeks in individuals with MASH and moderate (stage 2; F2) or severe (stage 3; F3) fibrosis.
835. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
作者: Patrick Rossignol.;Faiez Zannad.;Ziad Massy.;Michel Azizi.;Fatima Chorfa.;Julien Coadic.;João Pedro Ferreira.;Francisca Saraiva.;Dominique Mottier.;Francis Guillemin.;Willy Ngueyon Sime.;Sanae Bouali.;Bénédicte Rossignol.;Joëlle Nortier.;Isabelle Simon.;Christophe Robino.;Manuela Davin.;Pierre M Bataille.;François Chantrel.;Nelly Castin.;Vincent Esnault.;Isabelle Kazes.;Thierry Hannedouche.;Nassim Kamar.;Jean-Michel Achard.;Caroline Fenerol.;Carine Achard-Hottelart.;Yves Dimitrov.;Nicolas Girerd.;Delphine Maucort-Boulch.;Luc Frimat.; .
来源: Lancet. 2025年406卷10504期705-718页
No pharmacological therapy has been shown with certainty to improve the cardiovascular prognosis in patients with kidney failure on chronic haemodialysis. We aimed to investigate the effects of the steroidal mineralocorticoid receptor antagonist spironolactone on cardiovascular outcomes in patients on haemodialysis who are at high risk of cardiovascular events.
836. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
作者: Michael Walsh.;David Collister.;Martin Gallagher.;Patrick B Mark.;Janak R de Zoysa.;Jessica Tyrwhitt.;Karthik Tennankore.;Gilmar Reis.;Denis Xavier.;Wen J Liu.;Li Zuo.;Amanda Y Wang.;Camilo Félix.;Laura Sola.;Mustafa Arici.;Russell Villanueva.;Vivekanand Jha.;Dalton Précoma.;Christian G Rabbat.;Sheik Sulthan Alavudeen.;Atiya R Faruqui.;Mavel López-Flecher.;Lonnie Pyne.;Ron Wald.;Fei Yuan.;Kumar Balasubramanian.;Shun Fu Lee.;Alena Kuptsova.;Courtney Christou.;P J Devereaux.; .
来源: Lancet. 2025年406卷10504期695-704页
Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish if spironolactone reduces heart failure and cardiovascular deaths in these patients.
840. Global solidarity is needed now more than ever.
作者: Michelle Amri.;Colleen M Davison.;Lubna Bhayani.;Saad El-Din Hassan.;Frantz Jean Louis.;Nasreen Jessani.;Shahin Kassam.;Carly La Berge.;Tina Lines.;Yewande Kofoworola Ogundeji.;Nalini Singhal.
来源: Lancet. 2025年406卷10504期692-693页 |